Compare NTLA & BFC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NTLA | BFC |
|---|---|---|
| Founded | 2014 | 1894 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Major Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.7B |
| IPO Year | 2016 | 2018 |
| Metric | NTLA | BFC |
|---|---|---|
| Price | $13.03 | $139.95 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 18 | 2 |
| Target Price | $18.34 | ★ $150.00 |
| AVG Volume (30 Days) | ★ 4.0M | 69.0K |
| Earning Date | 01-01-0001 | 04-23-2026 |
| Dividend Yield | N/A | ★ 1.40% |
| EPS Growth | ★ 3.14 | N/A |
| EPS | N/A | ★ 5.36 |
| Revenue | ★ $57,877,000.00 | N/A |
| Revenue This Year | $1.71 | $58.67 |
| Revenue Next Year | N/A | $2.01 |
| P/E Ratio | ★ N/A | $26.67 |
| Revenue Growth | ★ 59.55 | N/A |
| 52 Week Low | $5.90 | $93.00 |
| 52 Week High | $28.24 | $153.00 |
| Indicator | NTLA | BFC |
|---|---|---|
| Relative Strength Index (RSI) | 54.55 | 48.37 |
| Support Level | $10.44 | $118.71 |
| Resistance Level | $14.61 | $140.92 |
| Average True Range (ATR) | 0.85 | 4.27 |
| MACD | -0.05 | -1.30 |
| Stochastic Oscillator | 68.14 | 14.32 |
Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.
Bank First Corp is a United States-based company engaged in providing financial services provides a full range of consumer and commercial financial institution services to individuals and businesses including retail and commercial banking in Wisconsin. These services include credit cards; secured and unsecured consumer, commercial, and real estate loans; demand, time, and savings deposits; and ATM processing. The Corporation also offers a full line of insurance services and checking accounts, savings accounts, money market accounts, cash management accounts, certificates of deposit, commercial and industrial loans, commercial real estate loans, construction and development loans, residential mortgages, consumer loans, credit cards, online banking, telephone banking, and mobile banking.